You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,928,074


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,928,074
Title:Combination therapy with co-stimulatory factors
Abstract: Methods for treating an inflammatory or an immune condition are described. Methods for treating an inflammatory or an immune condition with IL-1 inhibitors and an inhibitor of B cell or T cell activation are described. Methods for treating an inflammatory or an immune condition with TNF inhibitors and an inhibitor of B cell or T cell activation are described.
Inventor(s): Khare; Sanjay D. (Newbury Park, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:12/143,693
Patent Claims:1. A method for treating an individual afflicted with rheumatoid arthritis, which comprises administering a therapeutically effective amount of an IL-1 inhibitor and an OX40 ligand inhibitor to the individual, wherein the IL-1 inhibitor comprises an IL-1ra polypeptide and the OX40 ligand inhibitor comprises an antibody that binds OX40 ligand.

2. The method of claim 1, wherein the IL-1 inhibitor comprises an IL-1ra polypeptide fused to a human immunoglobulin constant region.

3. The method of claim 1, wherein the IL-1 inhibitor comprises Fc IL-1ra.

4. The method of claim 1, wherein the IL-1 inhibitor comprises the amino acid sequence of SEQ ID NO 3.

5. The method of claim 1, wherein the IL-1 inhibitor comprises anakinra.

6. The method of claim 1, wherein the administering is discontinued for at least one day and then resumed.

7. The method of claim 6, wherein the administering is resumed to treat a recurrence of the rheumatoid arthritis.

8. The method of claim 2, wherein the administering is discontinued for at least one day and then resumed.

9. The method of claim 8, wherein the administering is resumed to treat a recurrence of the rheumatoid arthritis.

10. The method of claim 3, wherein the administering is discontinued for at least one day and then resumed.

11. The method of claim 10, wherein the administering is resumed to treat a recurrence of the rheumatoid arthritis.

12. The method of claim 4, wherein the administering is discontinued for at least one day and then resumed.

13. The method of claim 12, wherein the administering is resumed to treat a recurrence of the rheumatoid arthritis.

14. The method of claim 5, wherein the administering is discontinued for at least one day and then resumed.

15. The method of claim 14, wherein the administering is resumed to treat a recurrence of the rheumatoid arthritis.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.